Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome)

Neuropathology

Volumn 31, Issue 5, 2011, Pages 531-539

  Haraguchi, Takashi ^a   Terada, Seishi ^b   Ishizu, Hideki ^c   Yokota, Osamu ^b   Yoshida, Hidenori ^a   Takeda, Naoya ^b   Kishimoto, Yuki ^b   Katayama, Naoko ^a   Takata, Hiroshi ^d   Akagi, Motohiro ^e   Kuroda, Shigetoshi ^c   Ihara, Yuetsu ^a   Uchitomi, Yosuke ^b  

^a Department of Internal Medicine   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c Department of Laboratory and Medicine   (Japan)

^d Kinashi Obayashi Hospital   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hallervorden Spatz syndrome; Neurodegeneration with brain iron accumulation type 1; Neurofibrillary change; Tauopathy; TDP 43 proteinopathy

Indexed keywords

ALPHA SYNUCLEIN; IRON; TAR DNA BINDING PROTEIN; TAU PROTEIN;

ADULT; AKINESIA; AKINETIC MUTISM; ARTICLE; AUTOPSY; BASAL GANGLION; BIOACCUMULATION; BRAIN ATROPHY; BRAIN CORTEX; BRAIN STEM; BRAIN WEIGHT; CASE REPORT; CELL INCLUSION; DEMENTIA; DENTATE GYRUS; FEMALE; FRONTAL CORTEX; GLOBUS PALLIDUS; GRANULE CELL; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MUSCLE RIGIDITY; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION TYPE 1; NEUROFIBRILLARY TANGLE; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; SYMPTOMATOLOGY; TEMPORAL CORTEX; TREMOR;

ATROPHY; BRAIN; DNA-BINDING PROTEINS; FATAL OUTCOME; FEMALE; HUMANS; IRON; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); TAU PROTEINS;

EID: 80053110031     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2010.01186.x     Document Type: Article

References (43)

1. Taylor TD, Litt M, Kramer P etal. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996; 14: 479-481.
2. Jellinger KA, Dura J. Neurodegeneration with brain iron accumulation, type 1 (Hallervorden-Spatz disease). In: Dickson D, ed. Pathology & Genetics: Neurodegenerative Diseases. Basel: ISN Neuropath Press, 2003; 394-399.
3. Arawaka S, Saito Y, Murayama S, Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 1998; 51: 887-889.
4. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28: 345-349.
5. Gordon N. Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome). Eur J Paediatr Neurol 2002; 6: 243-247.
6. Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden-Spatz syndrome. Arch Neurol 1974; 30: 70-83.
7. Jellinger K. Neuroaxonal dystrophy: its natural history and related disorders. In: Zimmerman H, ed. Progress in Neuropathology, Vol. 2. New York: Grune and Stratton, 1973; 129-180.
8. Park BE, Netsky MG, Betsill WL Jr. Pathogenesis of pigment and spheroid formation in Hallervorden-Spatz syndrome and related disorders. Neurology 1975; 25: 1172-1178.
9. Fuse S, Inoue K, Iwata M, Mannen T, Toyokura Y. An autopsy case of Hallervorden-Spatz disease with protracted course of about 30 years (in Japanese with English abstract). Neurol Med (Tokyo) 1987; 27: 155-167.
10. Newell KL, Boyer P, Gomez-Tortosa E etal. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonaldystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol 1999; 58: 1263-1268.
11. Wakabayashi K, Yoshimoto M, Fukushima T etal. Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol Appl Neurobiol 1999; 25: 363-368.
12. Neumann M, Adler S, Schluter O, Kremmer E, Benecke R, Kretzschmar HA. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol (Berl) 2000; 100: 568-574.
13. Wakabayashi K, Fukushima T, Koide R etal. Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and lewy body pathology. Acta Neuropathol (Berl) 2000; 99: 331-336.
14. Saito Y, Kawai M, Inoue K etal. Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci 2000; 177: 48-59.
15. Zarranz JJ, Gómez-Esteban JC, Atarés B, Lezcano E, Forcadas M. Tau-predominant-associated pathology in a sporadic late-onset Hallervorden-Spatz syndrome. Mov Disord 2006; 21: 107-111.
16. Tu PH, Galvin JE, Baba M etal. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998; 44: 415-422.
17. Wisniewski K, Jervis GA, Moretz RC, Wisniewski HM. Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia. Ann Neurol 1979; 5: 288-294.
18. Hartmann HA, White SK, Levine RL. Neuroaxonal dystrophy with neuromelanin deposition, neurofibrillary tangles, and neuronal loss: light- and electron-microscopic changes in a 45-year-old woman with progressive psychomotor deterioration. Acta Neuropathol (Berl) 1983; 61: 169-172.
19. Eidelberg D, Sotrel A, Joachim C etal. Adult onset Hallervorden-Spatz disease with neurofibrillary pathology: a discrete clinicopathological entity. Brain 1987; 110: 993-1013.
20. Yamamoto T, Kawamura J, Hashimoto S etal. Pallido-nigro-luysian atrophy, progressive supranuclear palsy and adult onset Hallervorden-Spatz disease: a case of akinesia as a predominant feature of Parkinsonism. J Neurol Sci 1991; 101: 98-106.
21. Takada K. Early occurrence of Alzheimer's neurofibrillary tangles (NFT) in developmental brain damage and chronic brain diseases with early childhood onset. Neuropathology 1993; 13: 333-335.
22. Halliday W. The nosology of Hallervorden-spatz disease. J Neurol Sci 1995; 134 (Suppl): 84-91.
23. Grimes DA, Lang AE, Bergeron C. Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. J Neurol Neurosurg Psychiatry 2000; 69: 392-395.
24. Gaytan-Garcia S, Kaufmann JC, Young GB. Adult onset Hallervorden-Spatz syndrome or Seitelberger's disease with late onset: variants of the same entity? A clinico-pathological study. Clin Neuropathol 1990; 9: 136-142.
25. Hayashi S, Akasaki Y, Morimura Y, Takauchi S, Sato M, Miyoshi K. An autopsy case of late infantile and juvenile neuroaxonal dystrophy with diffuse Lewy bodies and neurofibrillary tangles. Clin Neuropathol 1992; 11: 1-5.
26. Neumann M, Sampathu DM, Kwong LK etal. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-133.
27. Nakashima-Yasuda H, Uryu K, Robinson J etal. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 2007; 114: 221-229.
28. Geser F, Winton MJ, Kwong LK etal. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 2008; 115: 133-145.
29. Hasegawa M, Arai T, Akiyama H etal. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 2007; 130: 1386-1394.
30. Uryu K, Nakashima-Yasuda H, Forman MS etal. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008; 67: 555-564.
31. Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 2009; 29: 566-573.
32. Racette BA, Perry A, D'Avossa G, Perlmutter JS. Late-onset neurodegeneration with brain iron accumulation type 1: expanding the clinical spectrum. Mov Disord 2001; 16: 1148-1152.
33. Forman MS, Mackenzie IR, Cairns NJ etal. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 2006; 65: 571-581.
34. Mackenzie IR, Baborie A, Pickering-Brown S etal. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol (Berl) 2006; 112: 539-549.
35. Sampathu DM, Neumann M, Kwong LK etal. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 2006; 169: 1343-1352.
36. Cairns NJ, Bigio EH, Mackenzie IR etal. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl) 2007; 114: 5-22.
37. Amador-Ortiz C, Lin WL, Ahmed Z etal. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007; 61: 435-445.
38. Higashi S, Iseki E, Yamamoto R etal. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res 2007; 1184: 284-294.
39. Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of TDP-43 and huntingtin in inclusions of Huntington's disease. J Neuropathol Exp Neurol 2008; 67: 1159-1165.
40. Rozdilsky B, Bolton CF, Takeda M. Neuroaxonal dystrophy: a case of delayed onset and protracted course. Acta Neuropathol (Berl) 1971; 17: 331-340.
41. Hayflick SJ, Westaway SK, Levinson B etal. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003; 348: 33-40.
42. Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord 2004; 19: 36-42.
43. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 148-155.